Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Publication number: 20120183566Abstract: The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same.Type: ApplicationFiled: January 13, 2012Publication date: July 19, 2012Inventors: Robyn M. Barfield, Mark Alan Breidenbach, Gregory W. deHart, David Rabuka
-
Publication number: 20120177575Abstract: A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.Type: ApplicationFiled: July 21, 2010Publication date: July 12, 2012Applicant: Queen Mary & Westfield College University of LondonInventors: Davidson Day Ateh, Joanne Elizabeth Martin
-
Patent number: 8217153Abstract: Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography.Type: GrantFiled: January 25, 2010Date of Patent: July 10, 2012Assignee: Amgen Inc.Inventor: Joe Xin Hua Zhou
-
Publication number: 20120171120Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.Type: ApplicationFiled: November 29, 2011Publication date: July 5, 2012Applicant: Genentech, Inc.Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Joy Yu, Yin Zhang
-
Publication number: 20120171115Abstract: The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region (FR) 2 and/or at least two cysteine residues positioned within framework region (FR3), wherein if at least two of the cysteine residues in FR2 and/or FR3 are not conjugated to a compound then an intra-framework disulphide bond is capable of forming between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides conjugates of the protein and another compound.Type: ApplicationFiled: December 23, 2010Publication date: July 5, 2012Applicant: AVIPEP Pty LimitedInventors: Peter J. Hudson, Debra Tamvakis, Michael Paul Wheatcroft, Fabio Turatti
-
Patent number: 8211434Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: November 23, 2009Date of Patent: July 3, 2012Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Publication number: 20120164661Abstract: The present invention provides reagents containing binding moieties conjugated to dextran moieties, methods of making such reagents, and use of such reagents in a variety of molecular and cellular assays.Type: ApplicationFiled: September 22, 2011Publication date: June 28, 2012Applicant: BIOCEPT, INC.Inventors: Stephen D. MIKOLAJCZYK, Lisa S. MILLAR
-
Patent number: 8207311Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: GrantFiled: May 17, 2004Date of Patent: June 26, 2012Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20120156227Abstract: A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccinationType: ApplicationFiled: June 6, 2010Publication date: June 21, 2012Applicant: GAVISH-GALILEE BIO APPLICATIONS LTD.Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Alina Aizenshtein, Tal Gefen
-
Publication number: 20120156140Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.Type: ApplicationFiled: December 20, 2011Publication date: June 21, 2012Applicants: DYOMICS GMBH, PIERCE BIOTECHNOLOGY, INC.Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa Dworecki, Frank G. Lehmann
-
Publication number: 20120149061Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: December 9, 2011Publication date: June 14, 2012Inventors: NANCY E. STAGLIANO, JAMES W. WEST, KATHRYN KAMATH, PAUL H. BESSETTE, FREDERICK W. GLUCK, JASON SAGERT, PATRICK DAUGHERTY
-
Publication number: 20120149883Abstract: The invention provides a method detecting and quantifying proteins by mass spectrophotometric analysis using peptide internal standards and provides a highly sensitive way of detecting protein modifications. In one aspect, the invention provides a method for determining a site of ubiquitination in a polypeptide and for evaluating ubiquitination targets in a population of polypeptides. In this way, a proteome ubiquitination map can be obtained which comprises information relating to the ubiquitination states of a plurality of cellular polypeptides. Maps can be obtained for a variety of different types of cells and cell states. For example, ubiquitination targets in normal and diseased cells can be evaluated. Preferably, the map is stored as data files in a database. Individual ubiquitinated polypeptides identified can be used to generate molecular probes diagnostic of a cell state and/or can serve as targets for agents that modulate one or more cellular processes.Type: ApplicationFiled: October 28, 2011Publication date: June 14, 2012Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Steven P. Gygi, Junmin Peng
-
Publication number: 20120148580Abstract: The present disclosure relates to immunoglobulins and immunoglobulin conjugates with reduced oligomerization and efficient labeling and compositions, methods of generating such immunoglobulins and immunoglobulin conjugates and methods of using such immunoglobulin conjugates particularly in the treatment and prevention of disease.Type: ApplicationFiled: June 4, 2010Publication date: June 14, 2012Applicant: NOVARTIS AGInventors: Naresh Chennamsetty, Bernhard Helk, Voysel Kayser, Bernhardt Trout, Vladmir Voynov
-
Publication number: 20120148490Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne NcNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Patent number: 8198416Abstract: Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody.Type: GrantFiled: March 2, 2006Date of Patent: June 12, 2012Assignee: Universitaetsklinikum FreiburgInventors: Ursula Elsässer-Beile, Philipp Wolf, Dorothee Gierschner, Patrick Bühler, Ulrich Wetterauer
-
Publication number: 20120141416Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.Type: ApplicationFiled: June 30, 2010Publication date: June 7, 2012Applicant: Angiochem Inc.Inventors: Michel Demeule, Christian Che, Carine Thiot
-
Publication number: 20120141505Abstract: Provided herein are CD19-ligand (CD19-L) polypeptides and polynucleotides encoding such CD19-L polypeptides. Methods related to diagnosing and treating a disorder associated with CD19 positive B-cells in a patient using a CD19-L polypeptide are also provided.Type: ApplicationFiled: October 31, 2011Publication date: June 7, 2012Inventor: Fatih M. Uckun
-
Patent number: 8192740Abstract: An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention provides a novel method of cancer treatment using anti-GRP78 antibodies, novel cell growth inhibitors and anticancer agents that contain anti-GRP78 antibodies, as well as novel anti-GRP78 antibodies. The present inventor prepared antitumor antibodies to target GRP78, the localization of which in cancer cells changed to the cell membrane. The inventor successfully obtained an anti-GRP78 antibody that would bind specifically to the cell surface of cancer cells, leading to the accomplishment of the above-mentioned objects.Type: GrantFiled: February 27, 2008Date of Patent: June 5, 2012Assignee: Forerunner Pharma Research Co., Ltd.Inventor: Naoki Kimura
-
Patent number: 8193322Abstract: The present invention relates to monovalent antibody, methods of making thereof and therapeutic uses thereof. In particular, the present invention provides a heterodimeric polypeptide comprising an immunoglobulin heavy chain and a fusion protein comprising an immunoglobulin light chain and an Fc molecule.Type: GrantFiled: October 23, 2006Date of Patent: June 5, 2012Assignee: Amgen Inc.Inventors: Wei Yan, Michael Wittekind, Carla Forte
-
Publication number: 20120135012Abstract: Cell suicide (apoptosis) is associated with pathogenesis, for example, it is the major cause for the loss of neurons in Alzheimer's disease. Caspase-3 is critically involved in the pathway of apoptosis. Superantibody (SAT)-trans-membrane technology has been used to produce antibodies against the caspase enzyme in an effort to inhibit apoptosis in living cells. The advantage of using trans-membrane antibodies as apoptosis inhibitors is their specific target recognition in the cell and their lower toxicity compared to conventional apoptosis inhibitors. It is shown that a MTS-transport-peptide modified monoclonal anti-caspase-3 antibody reduces actinomycin D-induced apoptosis and cleavage of spectrin in living cells. These results indicate that antibodies conjugated to a membrane transporter peptide have a therapeutic potential to inhibit apoptosis in a variety of diseases.Type: ApplicationFiled: November 22, 2011Publication date: May 31, 2012Applicant: InNexus Biotechnology Inc.Inventors: Heinz Kohler, Sybille Müller, Thomas L. Brown, Yunfeng Zhao, A. Charles Morgan
-
Publication number: 20120136073Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: ApplicationFiled: November 15, 2011Publication date: May 31, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat du Jeu, Kristin Wiederholt
-
Patent number: 8187594Abstract: The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.Type: GrantFiled: June 12, 2009Date of Patent: May 29, 2012Assignee: MacroGenics, Inc.Inventors: Jennie P. Mather, Penelope E. Roberts, Ronghao Li
-
Patent number: 8188239Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.Type: GrantFiled: April 19, 2011Date of Patent: May 29, 2012Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, William J. McBride, Zhengxing Qu
-
Patent number: 8188240Abstract: The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy.Type: GrantFiled: December 12, 2011Date of Patent: May 29, 2012Assignee: Danisco US Inc.Inventors: Judith A. Fox, M. Harunur Rashid, Martin Roberge, Volker Schellenberger
-
Publication number: 20120129779Abstract: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.Type: ApplicationFiled: May 9, 2008Publication date: May 24, 2012Applicant: R&D-BIOPHARMACEUTICALS GMBHInventor: Wolfgang Richter
-
Publication number: 20120128700Abstract: A non-toxic polypeptide, for delivery of a therapeutic agent to a neuronal cell, comprises a binding domain that binds to the neuronal cell, and a translocation domain that translocates the therapeutic agent into the neuronal cell, wherein the translocation domain is not a HN domain of a clostridial toxin and is not a fragment or derivative of a HN domain of a clostridial toxin.Type: ApplicationFiled: February 1, 2012Publication date: May 24, 2012Applicant: SYNTAXIN LIMITEDInventors: Clifford Charles SHONE, John Mark SUTTON, Nigel SILMAN
-
Publication number: 20120129712Abstract: A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex.Type: ApplicationFiled: April 26, 2010Publication date: May 24, 2012Applicants: GLYKOS FINLAND OY, SUOMEN PUNAINEN RISTI, VERIPALVELUInventors: Tero Satomaa, Suvi Natunen, Leena Valmu, Jari Natunen
-
Publication number: 20120121576Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIA and uses for same.Type: ApplicationFiled: November 8, 2011Publication date: May 17, 2012Inventors: Jasbir Seehra, Erik Martinez-Hackert
-
Publication number: 20120122691Abstract: Disclosed are composites that comprise regenerated cellulose, a first active substance, a second active substance, and a linker. Methods for preparing the composites that involve the use of ionic liquids are also disclosed. Articles prepared from the disclosed composites and methods of using them are further disclosed.Type: ApplicationFiled: June 5, 2007Publication date: May 17, 2012Inventors: Daniel T. Daly, Scott K. Spear, Megan B. Turner, Whitney Lauren Hough, Robin D. Rogers
-
Publication number: 20120121512Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, or a detectable marker. These antibodies are of use to detect and/or isolate pancreatic cells or a subset thereof. Methods of treating a pancreatic tumor are also disclosed.Type: ApplicationFiled: December 13, 2011Publication date: May 17, 2012Inventors: Markus Grompe, Philip R. Streeter, Craig Dorrell, Stephanie L. Abraham, Kelsea M. Shoop
-
Publication number: 20120122238Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borreliae, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: ApplicationFiled: December 5, 2011Publication date: May 17, 2012Inventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jemlyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20120114558Abstract: The present invention relates to aptamer/drug conjugate complexes and the use of such complexes, together with a trigger compound, to inducibly release a drug. Through these complexes, the present invention provides a means for establishing a drug reservoir in a subject, whereby drug may be released as needed. One specific embodiment of the invention provides an aptamer/insulin conjugate complex from which insulin may be released by an innocuous, orally administrable trigger, such as quinine.Type: ApplicationFiled: September 26, 2011Publication date: May 10, 2012Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Milan N. Stojanovic, Renjun Pei, Steven Michael Forna Taylor
-
Publication number: 20120115136Abstract: The present invention pertains to certain nucleic acid analogs and related kits that are useful for the capture, recognition, detection, identification, or quantification of certain chemical or biological entities.Type: ApplicationFiled: July 25, 2011Publication date: May 10, 2012Applicant: PNA Patent Owners (a/k/a CIG)Inventors: Ole Buchardt, Michael Egholm, Peter E. Nielsen, Rolf H. Berg
-
Publication number: 20120117670Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.Type: ApplicationFiled: May 11, 2010Publication date: May 10, 2012Applicant: U3 PHARMA GMBHInventors: Peter Wirtz, Jens Ruhe, Takeshi Takilzawa, Tomoko Takayama
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120114602Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: ApplicationFiled: June 4, 2010Publication date: May 10, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Publication number: 20120117676Abstract: Compositions and methods related to transgenic AHAS-inhibiting herbicide resistant soybean plants are provided. Event 127 soybean plants having a mutated AHAS coding sequence which imparts tolerance to an AHAS-inhibiting herbicide are provided. The event 127 soybean plants having the event 127 nucleic acid molecule at the identified chromosomal location may comprise genomic/transgene junctions having at least the nucleic acid sequence of SEQ ID NO: 5 and/or 6. The characterization of the genomic insertion site of the event 127 provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the event 127 soybean plants are provided.Type: ApplicationFiled: January 6, 2010Publication date: May 10, 2012Inventors: Dale Carlson, Francisco Jose Lima Aragao, Carlos Alberto Arrabal Arias, Luiz Louzano, Bruce M. Luzzi, Tim Malefyt, Elibio Leopoldo Rech Filho, Siyuan Tan, Adolfo Ulbrich, Tadashi Yotsumoto, Ute Linemann
-
Publication number: 20120107335Abstract: The invention refers to the design, synthesis and evaluation of 6 synthetic oligopeptides, that have not been previously described, designed from the T and B epitopes of allergens of group I of intradomiciliary mites of the species Dermatophagoides pteronyssinus, Dermatophagoides farinae and Blomia tropicalis, which can be used in the immunomodulation of individuals having immunocompetent systems and in the production of IgY polyclonal antibodies. The invention relates to a first method for obtaining a composition of IgY polyclonal antibodies that can be used as a diagnostic reagent having low cost and high reactivity in respect of intradomiciliary mites, and a second method for the detection of mite allergens, using the IgY antibody composition developed in the first method. The invention further relates to the composition of the IgY polyclonal antibodies.Type: ApplicationFiled: March 17, 2010Publication date: May 3, 2012Applicants: PONTIFICIA UNIVERSIDAD JAVERIANA, FUNDACION UNIVERSIDAD DEL NORTEInventors: Luis Alejandro Barrera, Eduardo Egea, Johana Espejo, Catalina Sosa, Elkin Navarro, Gloria Garavito, Dary Luz Mendoza
-
Publication number: 20120107829Abstract: The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.Type: ApplicationFiled: March 31, 2010Publication date: May 3, 2012Applicant: LEUKOCARE AGInventors: Stefan Margraf, Anja Breuer, Martin Scholz, Jens Altrichter
-
Publication number: 20120108787Abstract: An immobilization particle for immobilizing a target microorganism or target chemical found in or on a mammal that includes: immobilization molecules capable of attaching to a target microorganism or a target chemical, which immobilization molecules are attached to one or more portions of a substrate structure; wherein the substrate structure is capable of inhibiting contact between tissues of the mammal and target microorganisms or target chemicals attached to immobilization molecules attached to the one or more portions.Type: ApplicationFiled: January 5, 2012Publication date: May 3, 2012Applicant: NUBIOME, INC.Inventor: Brian C. Lue
-
Publication number: 20120101007Abstract: A sensor for detecting of an analyte in a solution phase comprises a plurality of functionalised silver nanoplates wherein a functionalising agent is directly bonded to the surfaces of the nanoplates. The nanoplates provide a detectable wavelength shift change in their local surface plasmon resonance spectrum in response to the binding of an analyte. Two or more of the nanoplates may be electromagnetically coupled.Type: ApplicationFiled: April 8, 2010Publication date: April 26, 2012Applicants: PROVOST FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZEBETH NEA, NATIONAL UNIVERSITY OF IRELAND, GALWAYInventors: Damian Ahern, Margaret Brennan Fournet, Denise Charles, Stephen Michael Cunningham, Patrick Fournet, John Moffat Kelly, Deirdre Marie Ledwith, Muriel Celine Voisin
-
Publication number: 20120100141Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.Type: ApplicationFiled: March 24, 2010Publication date: April 26, 2012Inventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzta Pupecka
-
Publication number: 20120101260Abstract: A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components.Type: ApplicationFiled: April 16, 2011Publication date: April 26, 2012Inventors: Kathleen Cogan Farinas, Steven Chamow
-
Publication number: 20120100068Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.Type: ApplicationFiled: January 11, 2012Publication date: April 26, 2012Applicants: IMMUNOMEDICS, INC., THE OHIO STATE UNIVERSITYInventors: John C. Byrd, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8163887Abstract: Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tumor or an infectious agent. These immunoconjugates also comprise a peptide that contains an epitope of a tumor associated antigen or infectious agent antigen, a peptide that contains a minimal recognition unit of an anti-idiotype antibody, or a peptide that induces a strong major histocompatibility complex-restricted immune response. Antibodies and cytokines also may be used to amplify the immune cascade.Type: GrantFiled: January 15, 2008Date of Patent: April 24, 2012Assignee: Immunomedics, Inc.Inventor: Hans J. Hansen
-
Publication number: 20120093723Abstract: This invention provides multimeric nanocarrier for in vivo delivery of a bioactive agent, comprising at least two peptide monomers reversibly or irreversibly linked with one or more of said bioactive agents, wherein said two or more of said peptide monomers are covalently linked by a biodegradable difunctional moiety, as well as methods of using this nanocarrier.Type: ApplicationFiled: March 16, 2010Publication date: April 19, 2012Applicant: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Stanley Stein, Simi Gunaseelan, Shahrair Pooyan, Matthew S. Palombo, Xiaoping Zhang
-
Publication number: 20120094860Abstract: Methods for preparing an antibody are provided with the method including incorporating 3-bromo-4-hydroxy-benzoic acid into a protein to form an antigen, immunizing a mammalian host with the antigen, and recovering an antibody having an affinity for the antigen from the host. Antibodies having a binding affinity for a monohalotyrosine are provided as well as composition comprising an antibody bound with monohalotyrosine. Compositions comprising a protein having a 3-bromo-4-hydroxy-benzoic acid moiety are also provided. Methods for evaluating the severity of asthma are provide with the methods including analyzing sputum of a patient using an antibody having a binding affinity for monohalotyrosine, and measuring the amount of antibody bound to protein.Type: ApplicationFiled: October 19, 2011Publication date: April 19, 2012Inventors: Hongjun Jin, Richard C. Zangar
-
Publication number: 20120093731Abstract: Gas-filled microvesicles comprising a boundary envelope containing a gas, wherein said microvesicles comprise: —a first component, bound to said envelope, having binding affinity for an Fc-region of an antibody; and—a second component comprising a Fc-region of an antibody, bound to said first component through said Fc-region, said second component comprising a targeting ligand or a therapeutic agent. Aqueous suspensions of said microvesicles are particularly useful in contrast enhanced ultrasound imaging.Type: ApplicationFiled: December 19, 2007Publication date: April 19, 2012Applicant: Bracco Research S.A.Inventors: Eric Allemann, Thierry Bettinger, Philippe Bussat
-
Patent number: 8158124Abstract: Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.Type: GrantFiled: May 29, 2008Date of Patent: April 17, 2012Assignee: Lpath, Inc.Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, James Stephen Swaney
-
Publication number: 20120087911Abstract: This invention relates to a crystallisable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.Type: ApplicationFiled: November 29, 2011Publication date: April 12, 2012Applicant: RSR LIMITEDInventors: JANE SANDERS, JADWIGA FURMANIAK, BARNARD REES SMITH